Impact of Morning Light Therapy in IBD

Inclusion Criteria: * Patients with ulcerative colitis and signs of inflammation (Fecal calprotectin \>150 mcg/g and/or CRP \>5) Exclusion Criteria: * Known pregnancy or currently lactating women * Current malignancy or active treatment for previously diagnosed malignancy. Patients with squamous and basal cell cancer of the skin are eligible for the study. * Serious co-morbidity including: Immunodeficiency, recent myocardial infarction or stroke, history of renal or hepatic failure, infection such as abscess, opportunistic infection, or sepsis. * Patients with pacemaker or defibrillators * The use of medications known to affect autonomic nervous system function, including but not limited to beta-blockers and benzodiazepines. * Comprehension of the English language not adequate to understand the questionnaires * Recent changes in IBD directed therapies within the last 3 months * Regular use of antidiarrheal agents. * Regular use of medications that have been shown to impair sleep (e.g. steroids, stimulants). If willing (and medically appropriate) to washout for 4 weeks, participant can be then enrolled in the study * Regular use of sleep medications including but not limited to: benzodiazepine hypnotics, non-benzodiazepine hypnotics, antipsychotics, and melatonin. If willing (and medically appropriate) to washout for 4 weeks, participant can be then enrolled in the study * Patients with prior colectomy or total proctocolectomy * History of any surgery within 3 months * Untreated Obstructive Sleep Apnea * Blindness or severely impaired, uncorrected vision * Employment which includes nocturnal shift work * Traveling multiple time zones within the study time frame * Any marijuana or illicit drugs use within one month of enrollment or ongoing basis